2019
DOI: 10.3390/genes10090654
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges

Abstract: Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and have long been considered incurable. Following the successful development of a gene augmentation therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different therapeutic approaches are currently being developed, in particular a large variety of molecular therapies. These are depending on the severity of the retinal degeneration, knowledge of the pathophysiological mechanism underlyin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
71
0
3

Year Published

2020
2020
2022
2022

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 69 publications
(74 citation statements)
references
References 222 publications
(324 reference statements)
0
71
0
3
Order By: Relevance
“…We surmise that as more data is being gathered and analyzed, more deep-intronic and non-canonical splice site mutations will come to light [9], not only in IRD genes but also in other Mendelian diseases. Considering that among the most recently reported successful gene therapies for visual disorders, antisense oligonucleotides (AONs) are particularly promising to modulate the effect of splicing mutations [20][21][22][23][24][25], their characterization becomes crucial for patients carrying these variants in order to access these emerging therapies.…”
Section: Discussionmentioning
confidence: 99%
“…We surmise that as more data is being gathered and analyzed, more deep-intronic and non-canonical splice site mutations will come to light [9], not only in IRD genes but also in other Mendelian diseases. Considering that among the most recently reported successful gene therapies for visual disorders, antisense oligonucleotides (AONs) are particularly promising to modulate the effect of splicing mutations [20][21][22][23][24][25], their characterization becomes crucial for patients carrying these variants in order to access these emerging therapies.…”
Section: Discussionmentioning
confidence: 99%
“…C hannelrhodopsins are light-gated channels first discovered in green (chlorophyte) flagellate algae, in which they serve as photoreceptors mediating phototaxis by depolarization of the cell membrane (1)(2)(3). Currently, channelrhodopsins are widely used for control of neurons and other excitable cells with light ("optogenetics") (4) for research and also in clinical trials to restore vision to the blind (5). Channelrhodopsins from chlorophyte algae conduct cations and are therefore referred to as cation channelrhodopsins (CCRs).…”
mentioning
confidence: 99%
“…Advanced sequencing methods and the use of cell type-specific transcriptome and proteome and high-throughput screening systems of phenotypic and pleiotropic genetic effects analysis are aimed at identifying target genes associated with inherited diseases and provide prerequisites for better diagnostics, appropriate therapy technologies, and pharmacologic retinal protection [331,335,388,389].…”
Section: Conclusion/insightsmentioning
confidence: 99%